DBD (Dibromodulcitol)
Not specified (Orphan Designated)
Pre-clinical / Phase 1 pendingActive
Key Facts
Indication
Not specified (Orphan Designated)
Phase
Pre-clinical / Phase 1 pending
Status
Active
Company
About Eleison Pharmaceuticals
Eleison Pharmaceuticals is a private, pre-revenue biotech advancing a portfolio of three small molecule oncology candidates, all with Orphan Drug Designation. Its lead asset, glufosfamide, is in a pivotal Phase III trial for second-line pancreatic cancer, with top-line data expected in 2027. The company's strategy centers on developing 'uncommon therapies' for rare cancers by leveraging metabolic targeting to improve drug delivery and reduce toxicity.
View full company profile